$GILD Gilead Sciences Inc. Company Overview
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus/AIDS, liver diseases such as hepatitis B virus and hepatitis C virus, serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
GILD Last Price: 74.42
Last Updated: November 28, 2013 8:22 PM EST
GILD Stock Message Board and Forum http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Gilead Sciences Inc. GILD Officers and Executives
Name Age Officer Since Title
Dr. John C. Martin 61 1990 Chairman & Chief Executive Officer
Dr. John F. Milligan 52 1990 President & Chief Operating Officer
Ms. Robin L. Washington 50 2008 Chief Financial Officer & Senior Vice President
Dr. Muzammil M. Mansuri - 2010 SVP-Research & Development Strategy
Dr. Norbert W. Bischofberger 57 1990 Chief Scientific Officer & Executive VP-Research
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404
Phone
1 6505743000
Industry
Biotechnology
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$9.61B
Net Income
$2.59B
2012 Sales Growth
13.6%
Employees
5,000
Annual Report Below for GILD
Gilead Sciences Inc. GILD Recent Headlines
MarketWatch News on GILD
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns 10:16 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha
2014 FDA Drug Approval Decision Calendar 8:00 a.m. Nov. 27, 2013 - TheStreet.com
Four Biotech 'Surprise' Stocks for 2014 7:00 a.m. Nov. 27, 2013 - TheStreet.com
Surging Nasdaq Pierces 4000 8:11 p.m. Nov. 26, 2013 - WSJ.com
New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014 3:48 p.m. Nov. 26, 2013 - Seeking Alpha
Today's Market: These Stocks Will Push Nasdaq To All-Time Highs 11:00 a.m. Nov. 26, 2013 - Seeking Alpha
Gilead Sciences Inc's Buy Recommendation Supported 9:00 a.m. Nov. 26, 2013 - TheStreet.com
Most popular hedge fund shorts according to Goldman monitor 4:03 p.m. Nov. 25, 2013 - Seeking Alpha
Glaxo Shares Rise on Tivicay News - Analyst Blog 2:13 p.m. Nov. 25, 2013 - Zacks.com
Biogen & Gilead: Time To Ring the Cash Register? 12:35 p.m. Nov. 25, 2013 - Barrons.com
5 Drugs Stocks Moving The Industry Upward 12:03 p.m. Nov. 25, 2013 - TheStreet.com
Gilead Soars on Positive CHMP Opinion - Analyst Blog 11:50 a.m. Nov. 25, 2013 - Zacks.com
Stock Market News for November 25, 2013 - Market News 10:06 a.m. Nov. 25, 2013 - Zacks.com
New Lifetime High For Gilead (GILD) 9:48 a.m. Nov. 25, 2013 - TheStreet.com
Weekly CFO Sells Highlight: Gilead Sciences Inc., Prudential Financial Inc. ... 9:42 a.m. Nov. 25, 2013 - GuruFocus.com
4 Biotech Stocks With Upcoming FDA Decision Dates 9:14 a.m. Nov. 25, 2013 - Seeking Alpha
Gilead Sciences: 5 Different Insiders Have Sold Shares This Month 9:01 a.m. Nov. 25, 2013 - Seeking Alpha
Achillion Pharmaceuticals: 3 Different Insiders Have Purchased Shares This Month 8:59 a.m. Nov. 25, 2013 - Seeking Alpha
Press Releases on GILD
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA 9:47 a.m. Nov. 27, 2013 - ACCESSWIRE
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare 8:00 a.m. Nov. 27, 2013 - PR Newswire
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife 8:00 a.m. Nov. 25, 2013 - PR Newswire
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Valuation
P/E Current
45.51
P/E Ratio (with extraordinary items)
41.45
P/E Ratio (without extraordinary items)
22.39
Price to Sales Ratio
5.79
Price to Book Ratio
5.99
Price to Cash Flow Ratio
18.19
Enterprise Value to EBITDA
28.63
Enterprise Value to Sales
11.30
Total Debt to Enterprise Value
0.13
Efficiency
Revenue/Employee
1.92
Income Per Employee
0.52
Receivables Turnover
5.19
Total Asset Turnover
0.50
Liquidity
Current Ratio
1.44
Quick Ratio
1.03
Cash Ratio
0.44
Profitability
Gross Margin
74.29
Operating Margin
40.79
Pretax Margin
37.57
Net Margin
26.96
Return on Assets
13.45
Return on Equity
32.30
Return on Total Capital
16.18
Return on Invested Capital
16.80
Capital Structure
Total Debt to Total Equity
88.34
Total Debt to Total Capital
46.90
Total Debt to Total Assets
38.72
Long-Term Debt to Equity
75.78
Long-Term Debt to Total Capital
40.23
Gilead Sciences Inc. GILD Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 5.34B 6.93B 7.88B 8.46B 9.61B
Cost of Goods Sold (COGS) incl. D&A 1.13B 1.6B 1.87B 2.12B 2.47B
COGS excluding D&A 1.02B 1.38B 1.6B 1.82B 2.19B
Depreciation & Amortization Expense 102.47M 212.94M 265.48M 302.23M 278.21M
Depreciation 51.72M 64.56M 67.24M 72.19M 82.85M
Amortization of Intangibles 50.75M 148.38M 198.24M 230.05M 195.36M
Gross Income 4.21B 5.33B 6.01B 6.34B 7.14B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 1.52B 1.83B 2.09B 2.47B 3.22B
Research & Development 721.77M 914.22M 1.06B 1.23B 1.76B
Other SG&A 797.34M 912.09M 1.03B 1.24B 1.46B
Other Operating Expense 0 0 0 0 0
Unusual Expense 10.85M (9.41M) (115.36M) 56.56M (87.71M)
EBIT after Unusual Expense (10.85M) 9.41M 115.36M (56.56M) 87.71M
Non Operating Income/Expense 0 (29,000) (6.35M) 44.5M (36.18M)
Non-Operating Interest Income 59.4M 54.41M 0 0 0
Equity in Affiliates (Pretax) - 0 - 0 -
Interest Expense 12.1M 69.66M 108.96M 205.42M 360.92M
Gross Interest Expense 12.1M 69.66M 108.96M 205.42M 360.92M
Interest Capitalized 0 0 0 0 0
Pretax Income 2.73B 3.5B 3.91B 3.65B 3.61B
Income Tax 723.25M 876.36M 1.02B 861.95M 1.04B
Income Tax - Current Domestic 641.3M 873.15M 992.64M 767.04M 1.05B
Income Tax - Current Foreign 38.74M 42.86M 43.09M 39.92M 28.62M
Income Tax - Deferred Domestic 51.32M (38.46M) (12.39M) 50.94M (40.5M)
Income Tax - Deferred Foreign (8.11M) (1.19M) 454,000 4.04M (2.19M)
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 2B 2.63B 2.89B 2.79B 2.57B
Minority Interest Expense (8.56M) (10.16M) (11.51M) (14.58M) (17.97M)
Net Income 2.01B 2.64B 2.9B 2.8B 2.59B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 2.01B 2.64B 2.9B 2.8B 2.59B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 2.01B 2.64B 2.9B 2.8B 2.59B
EPS (Basic) 1.09 1.46 - 1.81 1.71
Basic Shares Outstanding 1.84B 1.81B 1.71B 1.55B 1.51B
EPS (Diluted) 1.05 1.41 1.66 1.78 1.64
Diluted Shares Outstanding 1.92B 1.87B 1.75B 1.58B 1.58B
EBITDA 2.79B 3.72B 4.18B 4.17B 4.2B
Gilead Sciences Inc. GILD Filings
SEC Filings for Gilead Sciences Inc.
Filing Date Document Date Type Category Amended
10/31/2013 09/30/2013 10-Q Quarterly Reports
10/29/2013 10/29/2013 8-K Special Events
08/09/2013 08/09/2013 8-K Special Events
08/01/2013 06/30/2013 10-Q Quarterly Reports
07/25/2013 07/25/2013 8-K Special Events
05/13/2013 05/08/2013 8-K Special Events
05/08/2013 03/31/2013 10-Q Quarterly Reports
05/02/2013 05/02/2013 8-K Special Events
03/19/2013 05/08/2013 DEF 14A Proxy Statement
03/08/2013 05/08/2013 PRE 14A Proxy Statement
02/27/2013 12/31/2012 10-K Annual Reports
02/14/2013 N/A SC 13G Institutional Ownership
02/13/2013 N/A SC 13G/A Institutional Ownership *
02/13/2013 N/A SC 13G Institutional Ownership
02/13/2013 N/A SC 13G Institutional Ownership
02/08/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 01/30/2013 8-K Special Events
02/04/2013 02/04/2013 8-K Special Events
01/31/2013 01/30/2013 8-K Special Events
12/12/2012 12/12/2012 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
GILD Gilead Sciences Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/GILD/quote
Stock Chart http://www.otcmarkets.com/stock/GILD/chart
Company Info http://www.otcmarkets.com/stock/GILD/company-info
Recent News http://www.otcmarkets.com/stock/GILD/news
Financials http://www.otcmarkets.com/stock/GILD/financials
Filings and Disclosure http://www.otcmarkets.com/stock/GILD/filings
Short Sales http://www.otcmarkets.com/stock/GILD/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/GILD/insider-transactions
Research Reports http://www.otcmarkets.com/stock/GILD/research
Summary http://finance.yahoo.com/q?s=GILD
Historical Prices http://finance.yahoo.com/q/hp?s=GILD+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=GILD
Basic Chart http://finance.yahoo.com/q/bc?s=GILD+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=GILD+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=GILD+Headlines
Press Releases http://finance.yahoo.com/q/p?s=GILD+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=GILD+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=GILD+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=GILD+Industry
Major Holders http://finance.yahoo.com/q/mh?s=GILD+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=GILD+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=GILD+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=GILD
Balance Sheet http://finance.yahoo.com/q/bs?s=GILD
Cash Flow http://finance.yahoo.com/q/cf?s=GILD+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/GILD
Market Watch http://www.marketwatch.com/investing/stock/GILD
Bloomberg http://www.bloomberg.com/quote/GILD:US
Morningstar http://quotes.morningstar.com/stock/s?t=GILD
Bussinessweek http://investing.businessweek.com/research/st...icker=GILD
Barchart http://www.barchart.com/quotes/stocks/GILD
OTC Short Report http://otcshortreport.com/index.php?index=GILD
Investopedia http://www.investopedia.com/markets/stocks/GILD/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus/AIDS, liver diseases such as hepatitis B virus and hepatitis C virus, serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
GILD Last Price: 74.42
Last Updated: November 28, 2013 8:22 PM EST
GILD Stock Message Board and Forum http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Gilead Sciences Inc. GILD Officers and Executives
Name Age Officer Since Title
Dr. John C. Martin 61 1990 Chairman & Chief Executive Officer
Dr. John F. Milligan 52 1990 President & Chief Operating Officer
Ms. Robin L. Washington 50 2008 Chief Financial Officer & Senior Vice President
Dr. Muzammil M. Mansuri - 2010 SVP-Research & Development Strategy
Dr. Norbert W. Bischofberger 57 1990 Chief Scientific Officer & Executive VP-Research
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404
Phone
1 6505743000
Industry
Biotechnology
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$9.61B
Net Income
$2.59B
2012 Sales Growth
13.6%
Employees
5,000
Annual Report Below for GILD
Gilead Sciences Inc. GILD Recent Headlines
MarketWatch News on GILD
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns 10:16 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha
2014 FDA Drug Approval Decision Calendar 8:00 a.m. Nov. 27, 2013 - TheStreet.com
Four Biotech 'Surprise' Stocks for 2014 7:00 a.m. Nov. 27, 2013 - TheStreet.com
Surging Nasdaq Pierces 4000 8:11 p.m. Nov. 26, 2013 - WSJ.com
New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014 3:48 p.m. Nov. 26, 2013 - Seeking Alpha
Today's Market: These Stocks Will Push Nasdaq To All-Time Highs 11:00 a.m. Nov. 26, 2013 - Seeking Alpha
Gilead Sciences Inc's Buy Recommendation Supported 9:00 a.m. Nov. 26, 2013 - TheStreet.com
Most popular hedge fund shorts according to Goldman monitor 4:03 p.m. Nov. 25, 2013 - Seeking Alpha
Glaxo Shares Rise on Tivicay News - Analyst Blog 2:13 p.m. Nov. 25, 2013 - Zacks.com
Biogen & Gilead: Time To Ring the Cash Register? 12:35 p.m. Nov. 25, 2013 - Barrons.com
5 Drugs Stocks Moving The Industry Upward 12:03 p.m. Nov. 25, 2013 - TheStreet.com
Gilead Soars on Positive CHMP Opinion - Analyst Blog 11:50 a.m. Nov. 25, 2013 - Zacks.com
Stock Market News for November 25, 2013 - Market News 10:06 a.m. Nov. 25, 2013 - Zacks.com
New Lifetime High For Gilead (GILD) 9:48 a.m. Nov. 25, 2013 - TheStreet.com
Weekly CFO Sells Highlight: Gilead Sciences Inc., Prudential Financial Inc. ... 9:42 a.m. Nov. 25, 2013 - GuruFocus.com
4 Biotech Stocks With Upcoming FDA Decision Dates 9:14 a.m. Nov. 25, 2013 - Seeking Alpha
Gilead Sciences: 5 Different Insiders Have Sold Shares This Month 9:01 a.m. Nov. 25, 2013 - Seeking Alpha
Achillion Pharmaceuticals: 3 Different Insiders Have Purchased Shares This Month 8:59 a.m. Nov. 25, 2013 - Seeking Alpha
Press Releases on GILD
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA 9:47 a.m. Nov. 27, 2013 - ACCESSWIRE
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare 8:00 a.m. Nov. 27, 2013 - PR Newswire
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife 8:00 a.m. Nov. 25, 2013 - PR Newswire
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Valuation
P/E Current
45.51
P/E Ratio (with extraordinary items)
41.45
P/E Ratio (without extraordinary items)
22.39
Price to Sales Ratio
5.79
Price to Book Ratio
5.99
Price to Cash Flow Ratio
18.19
Enterprise Value to EBITDA
28.63
Enterprise Value to Sales
11.30
Total Debt to Enterprise Value
0.13
Efficiency
Revenue/Employee
1.92
Income Per Employee
0.52
Receivables Turnover
5.19
Total Asset Turnover
0.50
Liquidity
Current Ratio
1.44
Quick Ratio
1.03
Cash Ratio
0.44
Profitability
Gross Margin
74.29
Operating Margin
40.79
Pretax Margin
37.57
Net Margin
26.96
Return on Assets
13.45
Return on Equity
32.30
Return on Total Capital
16.18
Return on Invested Capital
16.80
Capital Structure
Total Debt to Total Equity
88.34
Total Debt to Total Capital
46.90
Total Debt to Total Assets
38.72
Long-Term Debt to Equity
75.78
Long-Term Debt to Total Capital
40.23
Gilead Sciences Inc. GILD Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 5.34B 6.93B 7.88B 8.46B 9.61B
Cost of Goods Sold (COGS) incl. D&A 1.13B 1.6B 1.87B 2.12B 2.47B
COGS excluding D&A 1.02B 1.38B 1.6B 1.82B 2.19B
Depreciation & Amortization Expense 102.47M 212.94M 265.48M 302.23M 278.21M
Depreciation 51.72M 64.56M 67.24M 72.19M 82.85M
Amortization of Intangibles 50.75M 148.38M 198.24M 230.05M 195.36M
Gross Income 4.21B 5.33B 6.01B 6.34B 7.14B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 1.52B 1.83B 2.09B 2.47B 3.22B
Research & Development 721.77M 914.22M 1.06B 1.23B 1.76B
Other SG&A 797.34M 912.09M 1.03B 1.24B 1.46B
Other Operating Expense 0 0 0 0 0
Unusual Expense 10.85M (9.41M) (115.36M) 56.56M (87.71M)
EBIT after Unusual Expense (10.85M) 9.41M 115.36M (56.56M) 87.71M
Non Operating Income/Expense 0 (29,000) (6.35M) 44.5M (36.18M)
Non-Operating Interest Income 59.4M 54.41M 0 0 0
Equity in Affiliates (Pretax) - 0 - 0 -
Interest Expense 12.1M 69.66M 108.96M 205.42M 360.92M
Gross Interest Expense 12.1M 69.66M 108.96M 205.42M 360.92M
Interest Capitalized 0 0 0 0 0
Pretax Income 2.73B 3.5B 3.91B 3.65B 3.61B
Income Tax 723.25M 876.36M 1.02B 861.95M 1.04B
Income Tax - Current Domestic 641.3M 873.15M 992.64M 767.04M 1.05B
Income Tax - Current Foreign 38.74M 42.86M 43.09M 39.92M 28.62M
Income Tax - Deferred Domestic 51.32M (38.46M) (12.39M) 50.94M (40.5M)
Income Tax - Deferred Foreign (8.11M) (1.19M) 454,000 4.04M (2.19M)
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 2B 2.63B 2.89B 2.79B 2.57B
Minority Interest Expense (8.56M) (10.16M) (11.51M) (14.58M) (17.97M)
Net Income 2.01B 2.64B 2.9B 2.8B 2.59B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 2.01B 2.64B 2.9B 2.8B 2.59B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 2.01B 2.64B 2.9B 2.8B 2.59B
EPS (Basic) 1.09 1.46 - 1.81 1.71
Basic Shares Outstanding 1.84B 1.81B 1.71B 1.55B 1.51B
EPS (Diluted) 1.05 1.41 1.66 1.78 1.64
Diluted Shares Outstanding 1.92B 1.87B 1.75B 1.58B 1.58B
EBITDA 2.79B 3.72B 4.18B 4.17B 4.2B
Gilead Sciences Inc. GILD Filings
SEC Filings for Gilead Sciences Inc.
Filing Date Document Date Type Category Amended
10/31/2013 09/30/2013 10-Q Quarterly Reports
10/29/2013 10/29/2013 8-K Special Events
08/09/2013 08/09/2013 8-K Special Events
08/01/2013 06/30/2013 10-Q Quarterly Reports
07/25/2013 07/25/2013 8-K Special Events
05/13/2013 05/08/2013 8-K Special Events
05/08/2013 03/31/2013 10-Q Quarterly Reports
05/02/2013 05/02/2013 8-K Special Events
03/19/2013 05/08/2013 DEF 14A Proxy Statement
03/08/2013 05/08/2013 PRE 14A Proxy Statement
02/27/2013 12/31/2012 10-K Annual Reports
02/14/2013 N/A SC 13G Institutional Ownership
02/13/2013 N/A SC 13G/A Institutional Ownership *
02/13/2013 N/A SC 13G Institutional Ownership
02/13/2013 N/A SC 13G Institutional Ownership
02/08/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 01/30/2013 8-K Special Events
02/04/2013 02/04/2013 8-K Special Events
01/31/2013 01/30/2013 8-K Special Events
12/12/2012 12/12/2012 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
GILD Gilead Sciences Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/GILD/quote
Stock Chart http://www.otcmarkets.com/stock/GILD/chart
Company Info http://www.otcmarkets.com/stock/GILD/company-info
Recent News http://www.otcmarkets.com/stock/GILD/news
Financials http://www.otcmarkets.com/stock/GILD/financials
Filings and Disclosure http://www.otcmarkets.com/stock/GILD/filings
Short Sales http://www.otcmarkets.com/stock/GILD/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/GILD/insider-transactions
Research Reports http://www.otcmarkets.com/stock/GILD/research
Summary http://finance.yahoo.com/q?s=GILD
Historical Prices http://finance.yahoo.com/q/hp?s=GILD+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=GILD
Basic Chart http://finance.yahoo.com/q/bc?s=GILD+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=GILD+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=GILD+Headlines
Press Releases http://finance.yahoo.com/q/p?s=GILD+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=GILD+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=GILD+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=GILD+Industry
Major Holders http://finance.yahoo.com/q/mh?s=GILD+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=GILD+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=GILD+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=GILD
Balance Sheet http://finance.yahoo.com/q/bs?s=GILD
Cash Flow http://finance.yahoo.com/q/cf?s=GILD+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/GILD
Market Watch http://www.marketwatch.com/investing/stock/GILD
Bloomberg http://www.bloomberg.com/quote/GILD:US
Morningstar http://quotes.morningstar.com/stock/s?t=GILD
Bussinessweek http://investing.businessweek.com/research/st...icker=GILD
Barchart http://www.barchart.com/quotes/stocks/GILD
OTC Short Report http://otcshortreport.com/index.php?index=GILD
Investopedia http://www.investopedia.com/markets/stocks/GILD/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
